Moreover, EGFR has been reported to interact with AHR and GPER (G protein estrogen receptor) to stimulate breast cancer progression and EGFR can bypass RhoA to activate YAP signaling to promote hepatocellular carcinoma proliferation [35, 36]. Here, YAP1 is linked to hepatocellular carcinoma.